J&J HIV therapy approved by the US FDA for use in children
A HIV antiretroviral therapy, EDURANT®, from Johnson & Johnson has been granted approval from the US FDA for use in children with HIV-1 from the age of two.
HIV represents a huge burden on public health across the globe. In 2022 it was estimated that 39 million people were living with HIV, with the majority of those in Africa, and 2.58 million made up of children aged between 0 and 19 years old.
Now, the US FDA has approved the antiretroviral treatment EDURANT® PED (rilpivirine) from Johnson & Johnson for children. The therapy is used to HIV-1 in combination with other antiretroviral therapies in treatment naïve children, weighing between 14 and 25 kg.
J&J have pioneered HIV/AIDS treatment and aid since 1985, working with several charities and bodies to help those suffering across the world and give access to a range of treatment options that could help them. EDURANT® was initially approved in 2011, and after much testing and research J&J are pleased to announce the approval in paediatric patients with the disease.
“Decades of experience with the global HIV epidemic have made it clear that new and improved treatment options are needed to support the diverse population of people living with HIV on their treatment journey,” stated Penny Heaton, MD, Global Therapeutic Area Head, Infectious Diseases and Vaccines at Johnson & Johnson. “While the population of young children living with HIV is small, additional treatment options remain key to ensuring that each person living with HIV can be matched to a treatment regimen that is right for them.”
The approval comes after results from two clinical trials were released from J&J. The PAINT and PICTURE studies looked at paediatric patients, who were treated with rilpivirine in conjunction with other antiretrovirals. The results of the studies demonstrated that rilpivirine was effective in suppressing the HIV-1 virus in patients with HIV-1 RNA <100,000 copies/mL.
The dosing has been updated to include not only a 25 mg oral dosage (EDURANT®) but also a weight adjusted oral tablet of 2.5 mg, which is more suitable for children.
Source:
Johnson & Johnson. U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1. [Date accessed]. www.jnj.com/media-center/press-releases/u-s-fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance